JAK2V617F allelic frequency in patient samples and 6, 12, and 15 weeks after transplantation of CD34+ cells
| Patient . | Patients CD34+-derived colonies . | 6 weeks after treatment . | 12 weeks after treatment . | 15 weeks after treatment . | JAK2V617F/total JAK2 in human CD45+ from total BM 15 weeks after treatment, % . |
|---|---|---|---|---|---|
| PV1 | NA | NA | 0% (22/0/0) | NA | NA |
| PV2 | 9% (38/2/3) | 0% (35/0/0) | 0% (56/0/0) | NA | NA |
| PV3 | 38% (10/33/0) | 4% (71/7/0) | NA (0/0/0) | NA (0/0/0) | NA |
| PV4 | 22% (78/55/2) | 9% (78/16/0) | 1% (83/1/0) | 2% (45/2/0) | NA |
| PV5 | 36% (15/19/4) | 7% (25/4/0) | 0% (1/0/0) | 22% (5/4/0) | NA |
| PV6 | 24% (49/8/13) | 6% (68/7/1) | NA (0/0/0) | 0% (1/0/0) | 3 |
| PV7 | 36% (47/8/25) | 0% (92/0/0) | 0% (15/0/0) | 0% (2/0/0) | 0 |
| PV8 | 40% (9/38/0) | 0% (84/0/0) | 2% (45/2/0) | 4% (31/3/0) | 5 |
| PV9 | 33% (37/60/3) | 7% (101/17/0) | 5% (110/13/0) | 9% (65/14/0) | 1 |
| Mean PV ± SD | 30% ± 9% | 4% ± 3% | 1% ± 1% | 6% ± 6% | 2 ± 2 |
| PMF1 | 50% (0/70/0) | 50% (0/63/0) | 50% (0/169/0) | 50% (0/181/0) | 67 |
| PMF2 | 93% (1/10/81) | 98% (0/4/104) | 59% (8/45/21) | 64% (10/30/30) | 76 |
| PMF3 | 50% (0/72/0) | 50% (0/2/0) | NA (0/0/0) | NA (0/0/0) | 55 |
| PMF4 | 39% (41/64/15) | NA | 50% (0/2/1) | 63% (1/4/3) | NA |
| PMF5 | 52% (3/57/5) | 50% (2/17/2) | 50% (0/2/0) | NA (0/0/0) | 46 |
| PMF6 | 46% (1/12/0) | 50% (0/2/0) | NA (0/0/0) | NA (0/0/0) | 47 |
| Mean PMF ± SD | 55% ± 1% | 60% ± 15% | 52% ± 3% | 59% ± 6% | 58 ± 11 |
| PPV-MF1 | 80% (1/15/26) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | NA |
| PPV-MF2 | 100% (0/0/60) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | 95 |
| PPV-MF3 | 100% (0/0/79) | 100% (0/0/29) | 100% (0/0/2) | NA (0/0/0) | 96 |
| PPV-MF4 | 100% (0/0/44) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | NA |
| Mean PPV MF ± SD | 95% ± 7% | 100% | 100% | NA | 96 ± 1 |
| Patient . | Patients CD34+-derived colonies . | 6 weeks after treatment . | 12 weeks after treatment . | 15 weeks after treatment . | JAK2V617F/total JAK2 in human CD45+ from total BM 15 weeks after treatment, % . |
|---|---|---|---|---|---|
| PV1 | NA | NA | 0% (22/0/0) | NA | NA |
| PV2 | 9% (38/2/3) | 0% (35/0/0) | 0% (56/0/0) | NA | NA |
| PV3 | 38% (10/33/0) | 4% (71/7/0) | NA (0/0/0) | NA (0/0/0) | NA |
| PV4 | 22% (78/55/2) | 9% (78/16/0) | 1% (83/1/0) | 2% (45/2/0) | NA |
| PV5 | 36% (15/19/4) | 7% (25/4/0) | 0% (1/0/0) | 22% (5/4/0) | NA |
| PV6 | 24% (49/8/13) | 6% (68/7/1) | NA (0/0/0) | 0% (1/0/0) | 3 |
| PV7 | 36% (47/8/25) | 0% (92/0/0) | 0% (15/0/0) | 0% (2/0/0) | 0 |
| PV8 | 40% (9/38/0) | 0% (84/0/0) | 2% (45/2/0) | 4% (31/3/0) | 5 |
| PV9 | 33% (37/60/3) | 7% (101/17/0) | 5% (110/13/0) | 9% (65/14/0) | 1 |
| Mean PV ± SD | 30% ± 9% | 4% ± 3% | 1% ± 1% | 6% ± 6% | 2 ± 2 |
| PMF1 | 50% (0/70/0) | 50% (0/63/0) | 50% (0/169/0) | 50% (0/181/0) | 67 |
| PMF2 | 93% (1/10/81) | 98% (0/4/104) | 59% (8/45/21) | 64% (10/30/30) | 76 |
| PMF3 | 50% (0/72/0) | 50% (0/2/0) | NA (0/0/0) | NA (0/0/0) | 55 |
| PMF4 | 39% (41/64/15) | NA | 50% (0/2/1) | 63% (1/4/3) | NA |
| PMF5 | 52% (3/57/5) | 50% (2/17/2) | 50% (0/2/0) | NA (0/0/0) | 46 |
| PMF6 | 46% (1/12/0) | 50% (0/2/0) | NA (0/0/0) | NA (0/0/0) | 47 |
| Mean PMF ± SD | 55% ± 1% | 60% ± 15% | 52% ± 3% | 59% ± 6% | 58 ± 11 |
| PPV-MF1 | 80% (1/15/26) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | NA |
| PPV-MF2 | 100% (0/0/60) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | 95 |
| PPV-MF3 | 100% (0/0/79) | 100% (0/0/29) | 100% (0/0/2) | NA (0/0/0) | 96 |
| PPV-MF4 | 100% (0/0/44) | NA (0/0/0) | NA (0/0/0) | NA (0/0/0) | NA |
| Mean PPV MF ± SD | 95% ± 7% | 100% | 100% | NA | 96 ± 1 |
The BM aspirated from the right femur 6, 12, and 15 weeks after transplantation was seeded in methylcellulose, and human BFU-E and CFU-GM were picked and genotyped to look for the presence of the JAK2V617F mutation. DNA was also extracted from BM cells, and the proportion of JAK2V617F over total human JAK2 was quantified. The allelic frequency is the proportion of JAK2V617F alleles over total JAK2 alleles. Data are presented as the JAK2V617F allelic frequency (%) and data in parentheses are the numbers of BFU-E and CFU-GM that were genotyped (JAK2 wild-type/JAK2V617F heterozygous/JAK2V617F homozygous).
NA indicates not available.